{"id":"https://openalex.org/W2763004155","doi":"https://doi.org/10.1016/j.ejca.2017.08.032","title":"Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma","display_name":"Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma","publication_year":2017,"publication_date":"2017-10-05","ids":{"openalex":"https://openalex.org/W2763004155","doi":"https://doi.org/10.1016/j.ejca.2017.08.032","mag":"2763004155","pmid":"https://pubmed.ncbi.nlm.nih.gov/28987768"},"language":"en","primary_location":{"id":"doi:10.1016/j.ejca.2017.08.032","doi":"https://doi.org/10.1016/j.ejca.2017.08.032","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.ejca.2017.08.032","pdf_url":null,"source":{"id":"https://openalex.org/S16731738","display_name":"European Journal of Cancer","issn_l":"0959-8049","issn":["0959-8049","1879-0852"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Cancer","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.1016/j.ejca.2017.08.032","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5107877581","display_name":"Teresa M. Petrella","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1323843004","display_name":"Sunnybrook Health Science Centre","ror":"https://ror.org/03wefcv03","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1323843004"]},{"id":"https://openalex.org/I185261750","display_name":"University of Toronto","ror":"https://ror.org/03dbr7087","country_code":"CA","type":"education","lineage":["https://openalex.org/I185261750"]}],"countries":["CA"],"is_corresponding":true,"raw_author_name":"Teresa M. Petrella","raw_affiliation_strings":["Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Ave, T2-041, Toronto, ON, M4N 3M5, Canada. Electronic address: teresa.petrella@sunnybrook.ca","Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Ave, T2-041, Toronto, ON, M4N 3M5, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Ave, T2-041, Toronto, ON, M4N 3M5, Canada. Electronic address: teresa.petrella@sunnybrook.ca","institution_ids":["https://openalex.org/I1323843004","https://openalex.org/I185261750"]},{"raw_affiliation_string":"Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Ave, T2-041, Toronto, ON, M4N 3M5, Canada","institution_ids":["https://openalex.org/I1323843004","https://openalex.org/I185261750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100713900","display_name":"Caroline Robert","orcid":"https://orcid.org/0000-0002-9493-0238","observed_orcids":["https://orcid.org/0000-0002-9493-0238"]},"institutions":[{"id":"https://openalex.org/I102197404","display_name":"Universit\u00e9 Paris-Sud","ror":"https://ror.org/028rypz17","country_code":"FR","type":"education","lineage":["https://openalex.org/I102197404","https://openalex.org/I277688954"]},{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]}],"countries":["FR"],"is_corresponding":true,"raw_author_name":"Caroline Robert","raw_affiliation_strings":["Gustave Roussy and Universit\u00e9 Paris-Sud, 114 Rue Edouard Vaillant, 94800 Villejuif, France. Electronic address: caroline.robert@gustaveroussy.fr","Gustave Roussy and Universit\u00e9 Paris-Sud, 114 Rue Edouard Vaillant, 94800 Villejuif, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gustave Roussy and Universit\u00e9 Paris-Sud, 114 Rue Edouard Vaillant, 94800 Villejuif, France. Electronic address: caroline.robert@gustaveroussy.fr","institution_ids":["https://openalex.org/I102197404","https://openalex.org/I2801843802"]},{"raw_affiliation_string":"Gustave Roussy and Universit\u00e9 Paris-Sud, 114 Rue Edouard Vaillant, 94800 Villejuif, France","institution_ids":["https://openalex.org/I102197404","https://openalex.org/I2801843802"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007525817","display_name":"Erika Richtig","orcid":"https://orcid.org/0000-0002-5505-6103","observed_orcids":["https://orcid.org/0000-0002-5505-6103"]},"institutions":[{"id":"https://openalex.org/I202276237","display_name":"Medical University of Graz","ror":"https://ror.org/02n0bts35","country_code":"AT","type":"education","lineage":["https://openalex.org/I202276237"]}],"countries":["AT"],"is_corresponding":true,"raw_author_name":"Erika Richtig","raw_affiliation_strings":["Medical University of Graz, Auenbruggerpl. 2, 8036 Graz, Graz, Austria. Electronic address: erika.richtig@medunigraz.at","Medical University of Graz, Auenbruggerpl. 2, 8036 Graz, Graz, Austria"],"raw_orcid":"https://orcid.org/0000-0002-5505-6103","affiliations":[{"raw_affiliation_string":"Medical University of Graz, Auenbruggerpl. 2, 8036 Graz, Graz, Austria. Electronic address: erika.richtig@medunigraz.at","institution_ids":["https://openalex.org/I202276237"]},{"raw_affiliation_string":"Medical University of Graz, Auenbruggerpl. 2, 8036 Graz, Graz, Austria","institution_ids":["https://openalex.org/I202276237"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048013287","display_name":"Wilson H. Miller","orcid":"https://orcid.org/0000-0002-7408-1574","observed_orcids":["https://orcid.org/0000-0002-7408-1574"]},"institutions":[{"id":"https://openalex.org/I2801824472","display_name":"Jewish General Hospital","ror":"https://ror.org/056jjra10","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I2801824472","https://openalex.org/I2801902503","https://openalex.org/I4210139015","https://openalex.org/I4405256057","https://openalex.org/I4405279980"]},{"id":"https://openalex.org/I4405278727","display_name":"Rossy Cancer Network","ror":"https://ror.org/00f3ctm49","country_code":"CA","type":"funder","lineage":["https://openalex.org/I4405278727"]},{"id":"https://openalex.org/I5023651","display_name":"McGill University","ror":"https://ror.org/01pxwe438","country_code":"CA","type":"education","lineage":["https://openalex.org/I5023651"]}],"countries":["CA"],"is_corresponding":true,"raw_author_name":"Wilson H. Miller","raw_affiliation_strings":["Segal Cancer Centre, Jewish General Hospital, Rossy Cancer Network, and McGill University, 3755 Ch de la C\u00f4te-Sainte-Catherine, Montreal, QC, H3T 1E2, Canada. Electronic address: wilsonmiller@gmail.com","Segal Cancer Centre, Jewish General Hospital, Rossy Cancer Network, and McGill University, 3755 Ch de la C\u00f4te-Sainte-Catherine, Montreal, QC, H3T 1E2, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Segal Cancer Centre, Jewish General Hospital, Rossy Cancer Network, and McGill University, 3755 Ch de la C\u00f4te-Sainte-Catherine, Montreal, QC, H3T 1E2, Canada. Electronic address: wilsonmiller@gmail.com","institution_ids":["https://openalex.org/I2801824472","https://openalex.org/I4405278727","https://openalex.org/I5023651"]},{"raw_affiliation_string":"Segal Cancer Centre, Jewish General Hospital, Rossy Cancer Network, and McGill University, 3755 Ch de la C\u00f4te-Sainte-Catherine, Montreal, QC, H3T 1E2, Canada","institution_ids":["https://openalex.org/I2801824472","https://openalex.org/I4405278727","https://openalex.org/I5023651"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058125456","display_name":"Giuseppe Valentino Masucci","orcid":"https://orcid.org/0000-0002-9583-2306","observed_orcids":["https://orcid.org/0000-0002-9583-2306"]},"institutions":[{"id":"https://openalex.org/I28166907","display_name":"Karolinska Institutet","ror":"https://ror.org/056d84691","country_code":"SE","type":"education","lineage":["https://openalex.org/I28166907"]}],"countries":["SE"],"is_corresponding":true,"raw_author_name":"Giuseppe V. Masucci","raw_affiliation_strings":["Karolinska Institute, Solnav\u00e4gen 1, 171 77 Solna, Stockholm, Sweden. Electronic address: giuseppe.masucci@ki.se","Karolinska Institute, Solnav\u00e4gen 1, 171 77 Solna, Stockholm, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Karolinska Institute, Solnav\u00e4gen 1, 171 77 Solna, Stockholm, Sweden. Electronic address: giuseppe.masucci@ki.se","institution_ids":["https://openalex.org/I28166907"]},{"raw_affiliation_string":"Karolinska Institute, Solnav\u00e4gen 1, 171 77 Solna, Stockholm, Sweden","institution_ids":["https://openalex.org/I28166907"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076399397","display_name":"Euan Thomas Walpole","orcid":"https://orcid.org/0000-0001-6105-9039","observed_orcids":["https://orcid.org/0000-0001-6105-9039"]},"institutions":[{"id":"https://openalex.org/I165143802","display_name":"The University of Queensland","ror":"https://ror.org/00rqy9422","country_code":"AU","type":"education","lineage":["https://openalex.org/I165143802"]},{"id":"https://openalex.org/I2801814493","display_name":"Princess Alexandra Hospital","ror":"https://ror.org/04mqb0968","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I1302211766","https://openalex.org/I2801244131","https://openalex.org/I2801814493","https://openalex.org/I4210089726"]}],"countries":["AU"],"is_corresponding":true,"raw_author_name":"Euan Walpole","raw_affiliation_strings":["Princess Alexandra Hospital and The University of Queensland, 199 Ipswich Rd, Woolloongabba, Brisbane, QLD 4102, Australia. Electronic address: euan.walpole@health.qld.gov.au","Princess Alexandra Hospital and The University of Queensland, 199 Ipswich Rd, Woolloongabba, Brisbane, QLD 4102, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Princess Alexandra Hospital and The University of Queensland, 199 Ipswich Rd, Woolloongabba, Brisbane, QLD 4102, Australia. Electronic address: euan.walpole@health.qld.gov.au","institution_ids":["https://openalex.org/I165143802","https://openalex.org/I2801814493"]},{"raw_affiliation_string":"Princess Alexandra Hospital and The University of Queensland, 199 Ipswich Rd, Woolloongabba, Brisbane, QLD 4102, Australia","institution_ids":["https://openalex.org/I165143802","https://openalex.org/I2801814493"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025478490","display_name":"C\u00e9l\u00e8ste Lebb\u00e9","orcid":"https://orcid.org/0000-0002-5854-7290","observed_orcids":["https://orcid.org/0000-0002-5854-7290"]},"institutions":[{"id":"https://openalex.org/I4210097159","display_name":"Assistance Publique \u2013 H\u00f4pitaux de Paris","ror":"https://ror.org/00pg5jh14","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210097159"]},{"id":"https://openalex.org/I4210144610","display_name":"H\u00f4pital Saint-Louis","ror":"https://ror.org/049am9t04","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210097159","https://openalex.org/I4210144610"]},{"id":"https://openalex.org/I4387154366","display_name":"Universit\u00e9 Paris Diderot","ror":"https://ror.org/02n7qrg46","country_code":"FR","type":"education","lineage":["https://openalex.org/I204730241","https://openalex.org/I4387154366"]}],"countries":["FR"],"is_corresponding":true,"raw_author_name":"Celeste Lebbe","raw_affiliation_strings":["APHP, Dermatology and CIC, Universit\u00e9 Paris Diderot, H\u00f4pital Saint-Louis, 1 Avenue Claude Vellefaux, 75010 Paris, France. Electronic address: celeste.lebbe@aphp.fr","APHP, Dermatology and CIC, Universit\u00e9 Paris Diderot, H\u00f4pital Saint-Louis, 1 Avenue Claude Vellefaux, 75010 Paris, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"APHP, Dermatology and CIC, Universit\u00e9 Paris Diderot, H\u00f4pital Saint-Louis, 1 Avenue Claude Vellefaux, 75010 Paris, France. Electronic address: celeste.lebbe@aphp.fr","institution_ids":["https://openalex.org/I4210097159","https://openalex.org/I4210144610","https://openalex.org/I4387154366"]},{"raw_affiliation_string":"APHP, Dermatology and CIC, Universit\u00e9 Paris Diderot, H\u00f4pital Saint-Louis, 1 Avenue Claude Vellefaux, 75010 Paris, France","institution_ids":["https://openalex.org/I4210097159","https://openalex.org/I4210144610","https://openalex.org/I4387154366"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040801002","display_name":"Neil Matthew Steven","orcid":"https://orcid.org/0000-0002-0571-5043","observed_orcids":["https://orcid.org/0000-0002-0571-5043"]},"institutions":[{"id":"https://openalex.org/I2799307867","display_name":"Queen Elizabeth Hospital Birmingham","ror":"https://ror.org/048emj907","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1308923049","https://openalex.org/I2799307867"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"Neil Steven","raw_affiliation_strings":["Queen Elizabeth Hospital Birmingham, Mindelsohn Way, Birmingham B15 2TH, UK. Electronic address: N.M.Steven@bham.ac.uk","Queen Elizabeth Hospital Birmingham, Mindelsohn Way, Birmingham B15 2TH, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Queen Elizabeth Hospital Birmingham, Mindelsohn Way, Birmingham B15 2TH, UK. Electronic address: N.M.Steven@bham.ac.uk","institution_ids":["https://openalex.org/I2799307867"]},{"raw_affiliation_string":"Queen Elizabeth Hospital Birmingham, Mindelsohn Way, Birmingham B15 2TH, UK","institution_ids":["https://openalex.org/I2799307867"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051430596","display_name":"Mark Ross Middleton","orcid":"https://orcid.org/0000-0003-0167-1685","observed_orcids":["https://orcid.org/0000-0003-0167-1685"]},"institutions":[{"id":"https://openalex.org/I2801179840","display_name":"Churchill Hospital","ror":"https://ror.org/009vheq40","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2801179840","https://openalex.org/I4210147381"]},{"id":"https://openalex.org/I40120149","display_name":"University of Oxford","ror":"https://ror.org/052gg0110","country_code":"GB","type":"education","lineage":["https://openalex.org/I40120149"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"Mark R. Middleton","raw_affiliation_strings":["The Churchill Hospital and The University of Oxford, Old Rd, Headington, Oxford OX3 7LE, UK. Electronic address: mark.middleton@oncology.ox.ac.uk","The Churchill Hospital and The University of Oxford, Old Rd, Headington, Oxford OX3 7LE, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Churchill Hospital and The University of Oxford, Old Rd, Headington, Oxford OX3 7LE, UK. Electronic address: mark.middleton@oncology.ox.ac.uk","institution_ids":["https://openalex.org/I2801179840","https://openalex.org/I40120149"]},{"raw_affiliation_string":"The Churchill Hospital and The University of Oxford, Old Rd, Headington, Oxford OX3 7LE, UK","institution_ids":["https://openalex.org/I2801179840","https://openalex.org/I40120149"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001099943","display_name":"Darcy A. Hille","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Darcy Hille","raw_affiliation_strings":["Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA. Electronic address: darcy_hille@merck.com","Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA. Electronic address: darcy_hille@merck.com","institution_ids":["https://openalex.org/I1285764155"]},{"raw_affiliation_string":"Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037996246","display_name":"Wei Zhou","orcid":"https://orcid.org/0000-0003-0224-2559","observed_orcids":["https://orcid.org/0000-0003-0224-2559"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Wei Zhou","raw_affiliation_strings":["Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA. Electronic address: wei.zhou2@merck.com","Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA. Electronic address: wei.zhou2@merck.com","institution_ids":["https://openalex.org/I1285764155"]},{"raw_affiliation_string":"Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037357027","display_name":"Nageatte Ibrahim","orcid":"https://orcid.org/0000-0003-0794-949X","observed_orcids":["https://orcid.org/0000-0003-0794-949X"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Nageatte Ibrahim","raw_affiliation_strings":["Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA. Electronic address: nageatte.ibrahim@merck.com","Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA. Electronic address: nageatte.ibrahim@merck.com","institution_ids":["https://openalex.org/I1285764155"]},{"raw_affiliation_string":"Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5031661938","display_name":"Jonathan Simon Cebon","orcid":"https://orcid.org/0000-0002-3898-950X","observed_orcids":["https://orcid.org/0000-0002-3898-950X"]},"institutions":[{"id":"https://openalex.org/I196829312","display_name":"La Trobe University","ror":"https://ror.org/01rxfrp27","country_code":"AU","type":"education","lineage":["https://openalex.org/I196829312"]},{"id":"https://openalex.org/I4210163497","display_name":"Austin Health","ror":"https://ror.org/05dbj6g52","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I4210163497"]},{"id":"https://openalex.org/I4405265871","display_name":"Olivia Newton-John Cancer Research Institute","ror":"https://ror.org/05yncf830","country_code":"AU","type":"nonprofit","lineage":["https://openalex.org/I196829312","https://openalex.org/I4210158799","https://openalex.org/I4405265871"]}],"countries":["AU"],"is_corresponding":true,"raw_author_name":"Jonathan Cebon","raw_affiliation_strings":["Olivia Newton-John Cancer Research Institute, Austin Health, School of Cancer Medicine, La Trobe University, 145 Studley Road, Heidelberg VIC 3084, Melbourne, Australia. Electronic address: jonathan.cebon@onjcri.org.au","Olivia Newton-John Cancer Research Institute, Austin Health, School of Cancer Medicine, La Trobe University, 145 Studley Road, Heidelberg VIC 3084, Melbourne, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Olivia Newton-John Cancer Research Institute, Austin Health, School of Cancer Medicine, La Trobe University, 145 Studley Road, Heidelberg VIC 3084, Melbourne, Australia. Electronic address: jonathan.cebon@onjcri.org.au","institution_ids":["https://openalex.org/I196829312","https://openalex.org/I4210163497","https://openalex.org/I4405265871"]},{"raw_affiliation_string":"Olivia Newton-John Cancer Research Institute, Austin Health, School of Cancer Medicine, La Trobe University, 145 Studley Road, Heidelberg VIC 3084, Melbourne, Australia","institution_ids":["https://openalex.org/I196829312","https://openalex.org/I4210163497","https://openalex.org/I4405265871"]}]}],"institutions":[],"countries_distinct_count":7,"institutions_distinct_count":21,"corresponding_author_ids":["https://openalex.org/A5001099943","https://openalex.org/A5007525817","https://openalex.org/A5025478490","https://openalex.org/A5031661938","https://openalex.org/A5037357027","https://openalex.org/A5037996246","https://openalex.org/A5040801002","https://openalex.org/A5048013287","https://openalex.org/A5051430596","https://openalex.org/A5058125456","https://openalex.org/A5076399397","https://openalex.org/A5100713900","https://openalex.org/A5107877581"],"corresponding_institution_ids":["https://openalex.org/I102197404","https://openalex.org/I1285764155","https://openalex.org/I1323843004","https://openalex.org/I165143802","https://openalex.org/I185261750","https://openalex.org/I196829312","https://openalex.org/I202276237","https://openalex.org/I2799307867","https://openalex.org/I2801179840","https://openalex.org/I2801814493","https://openalex.org/I2801824472","https://openalex.org/I2801843802","https://openalex.org/I28166907","https://openalex.org/I40120149","https://openalex.org/I4210097159","https://openalex.org/I4210144610","https://openalex.org/I4210163497","https://openalex.org/I4387154366","https://openalex.org/I4405265871","https://openalex.org/I4405278727","https://openalex.org/I5023651"],"apc_list":{"value":4270,"currency":"USD","value_usd":4270},"apc_paid":{"value":4270,"currency":"USD","value_usd":4270},"fwci":6.1521,"has_fulltext":false,"cited_by_count":91,"citation_normalized_percentile":{"value":0.97825415,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":95,"max":100},"biblio":{"volume":"86","issue":null,"first_page":"115","last_page":"124"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.8794000148773193,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.8794000148773193,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.06390000134706497,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10178","display_name":"Cancer survivorship and care","score":0.033799998462200165,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/patient-reported-outcomes","display_name":"patient-reported outcomes","score":0.796999990940094},{"id":"https://openalex.org/keywords/health-related-quality-of-life","display_name":"health-related quality of life","score":0.9800000190734863},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.972000002861023},{"id":"https://openalex.org/keywords/ipilimumab","display_name":"ipilimumab","score":1.0},{"id":"https://openalex.org/keywords/advanced-melanoma","display_name":"advanced melanoma","score":0.9900000095367432},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.8550000190734863},{"id":"https://openalex.org/keywords/eortc-qlq-c30","display_name":"EORTC QLQ-C30","score":0.9409999847412109},{"id":"https://openalex.org/keywords/global-health-status","display_name":"global health status","score":0.8840000033378601},{"id":"https://openalex.org/keywords/treatment-related-symptoms","display_name":"treatment-related symptoms","score":0.531000018119812},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.7440000176429749},{"id":"https://openalex.org/keywords/immune-related-encephalitis","display_name":"immune-related encephalitis","score":0.46799999475479126},{"id":"https://openalex.org/keywords/immune-mediated-colitis","display_name":"immune-related colitis","score":0.6179999709129333}],"concepts":[{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.9514449834823608},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.9423470497131348},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8989599943161011},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4941613972187042},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4928860664367676},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.4226977825164795},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.18104973435401917},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.060568004846572876},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.04267612099647522}],"mesh":[{"descriptor_ui":"D000071066","descriptor_name":"Patient Reported Outcome Measures","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000074324","descriptor_name":"Ipilimumab","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000074324","descriptor_name":"Ipilimumab","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006304","descriptor_name":"Health Status","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011788","descriptor_name":"Quality of Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D013997","descriptor_name":"Time Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.1016/j.ejca.2017.08.032","doi":"https://doi.org/10.1016/j.ejca.2017.08.032","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.ejca.2017.08.032","pdf_url":null,"source":{"id":"https://openalex.org/S16731738","display_name":"European Journal of Cancer","issn_l":"0959-8049","issn":["0959-8049","1879-0852"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Cancer","raw_type":"journal-article"},{"id":"pmid:28987768","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/28987768","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European journal of cancer (Oxford, England : 1990)","raw_type":"Clinical Trial, Phase III"},{"id":"pmh:oai:ora.ox.ac.uk:uuid:8e7057b8-5a94-4c1f-ab99-6eee88bcf098","doi":null,"is_oa":true,"landing_page_url":"https://ora.ox.ac.uk/objects/uuid:8e7057b8-5a94-4c1f-ab99-6eee88bcf098/files/m5c3cfc9fbf7ce958b20e8c5fbacf80f5","pdf_url":null,"source":{"id":"https://openalex.org/S4306402636","display_name":"Oxford University Research Archive (ORA) (University of Oxford)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I40120149","host_organization_name":"University of Oxford","host_organization_lineage":["https://openalex.org/I40120149"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Symplectic Elements at Oxford","raw_type":"Journal article"}],"best_oa_location":{"id":"doi:10.1016/j.ejca.2017.08.032","doi":"https://doi.org/10.1016/j.ejca.2017.08.032","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.ejca.2017.08.032","pdf_url":null,"source":{"id":"https://openalex.org/S16731738","display_name":"European Journal of Cancer","issn_l":"0959-8049","issn":["0959-8049","1879-0852"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Cancer","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307776","display_name":"Merck","ror":"https://ror.org/02891sr49"},{"id":"https://openalex.org/F4320333967","display_name":"Alcohol and Drug Abuse Institute, University of Washington","ror":null}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":32,"referenced_works":["https://openalex.org/W1809627231","https://openalex.org/W1893566975","https://openalex.org/W1947168884","https://openalex.org/W1965939250","https://openalex.org/W2017712207","https://openalex.org/W2018304470","https://openalex.org/W2028552358","https://openalex.org/W2042647626","https://openalex.org/W2055753418","https://openalex.org/W2066671159","https://openalex.org/W2067212858","https://openalex.org/W2081447339","https://openalex.org/W2097995306","https://openalex.org/W2098428600","https://openalex.org/W2104998041","https://openalex.org/W2111131433","https://openalex.org/W2114649921","https://openalex.org/W2115747377","https://openalex.org/W2123363005","https://openalex.org/W2144547008","https://openalex.org/W2150048477","https://openalex.org/W2150153870","https://openalex.org/W2152897456","https://openalex.org/W2160410413","https://openalex.org/W2167571044","https://openalex.org/W2473786944","https://openalex.org/W2491364075","https://openalex.org/W2510967925","https://openalex.org/W2583263803","https://openalex.org/W2636042323","https://openalex.org/W3175138720","https://openalex.org/W6722775521"],"related_works":["https://openalex.org/W2510967925","https://openalex.org/W2595962063","https://openalex.org/W2947449664","https://openalex.org/W4300772409","https://openalex.org/W2797763586","https://openalex.org/W3024501588","https://openalex.org/W4281826523","https://openalex.org/W2947602393","https://openalex.org/W2114649921","https://openalex.org/W2914792906"],"abstract_inverted_index":{"OBJECTIVE:":[0],"Report":[1],"results":[2],"of":[3,7,17,51,63,66,191],"patient-reported":[4],"health-related":[5],"quality":[6],"life":[8],"(HRQoL)":[9],"and":[10,61,76,160,171,193,229,240],"symptoms":[11,241],"from":[12,96],"phase":[13],"III":[14],"KEYNOTE-006":[15],"study":[16],"pembrolizumab":[18,32,125,130,167,169,186,196,206,214,224,249],"versus":[19,197,208],"ipilimumab":[20,52,135,172,189,252],"in":[21,101,217,253],"patients":[22,211,254],"with":[23,185,188,213,233,248,251,255],"ipilimumab-naive":[24,256],"advanced":[25,257],"melanoma.":[26,258],"PATIENTS":[27],"AND":[28],"METHODS:":[29],"Patients":[30],"received":[31],"10":[33],"mg/kg":[34,54],"every":[35,39],"2":[36,46],"(Q2W)":[37],"or":[38,48],"3":[40,53],"weeks":[41],"(Q3W)":[42],"for":[43,59,165,195,199,204,223,227,231,237],"up":[44],"to":[45,98,177],"years,":[47],"four":[49],"cycles":[50],"Q3W.":[55],"The":[56,118],"European":[57],"Organisation":[58],"Research":[60],"Treatment":[62],"Cancer":[64],"Quality":[65],"Life":[67],"Questionnaire":[68],"C30":[69],"(EORTC":[70],"QLQ-C30)":[71],"was":[72,92,141,245],"administered":[73],"at":[74,148,219],"baseline":[75,97,176],"throughout":[77],"the":[78,88,93,110,166],"study.":[79],"Patient-reported":[80],"outcome":[81],"(PRO)":[82],"analyses":[83],"were":[84,151,182],"pre-specified":[85],"exploratory":[86],"endpoints;":[87],"primary":[89],"PRO":[90,119],"assessment":[91],"score":[94,108],"change":[95],"week":[99,149,178,220],"12":[100,150,221],"EORTC":[102],"QLQ-C30":[103,145],"global":[104],"health":[105],"status":[106],"(GHS)/HRQoL":[107],"between":[109],"arms":[111],"using":[112],"constrained":[113],"longitudinal":[114],"data":[115],"analysis.":[116],"RESULTS:":[117],"analysis":[120],"population":[121],"included":[122],"776":[123],"patients:":[124],"Q2W":[126],"(n":[127,132,136,153,157,162],"=":[128,133,137,154,158,163],"270);":[129],"Q3W":[131,228],"266);":[134],"240).":[138],"Baseline":[139],"GHS":[140,218],"similar":[142,234],"across":[143],"arms.":[144],"compliance":[146],"rates":[147],"87%":[152],"214),":[155],"97%":[156],"226),":[159],"96%":[161],"178),":[164],"Q2W,":[168],"Q3W,":[170],"arms,":[173],"respectively.":[174],"From":[175],"12,":[179],"GHS/HRQoL":[180],"scores":[181],"better":[183,246],"maintained":[184,247],"than":[187,250],"(decrease":[190],"-1.9":[192],"-2.5":[194],"-10.0":[198],"ipilimumab;":[200],"p":[201],"<":[202],"0.001":[203],"each":[205],"arm":[207],"ipilimumab).":[209],"Fewer":[210],"treated":[212],"experienced":[215],"deterioration":[216],"(31%":[222],"Q2W;":[225],"29%":[226],"44%":[230],"ipilimumab),":[232],"trends":[235],"observed":[236],"individual":[238],"functioning":[239],"scales.":[242],"CONCLUSIONS:":[243],"HRQoL":[244],"CLINICALTRIALS.":[259],"GOV":[260],"IDENTIFIER:":[261],"NCT01866319.":[262]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":6},{"year":2024,"cited_by_count":9},{"year":2023,"cited_by_count":8},{"year":2022,"cited_by_count":8},{"year":2021,"cited_by_count":11},{"year":2020,"cited_by_count":23},{"year":2019,"cited_by_count":17},{"year":2018,"cited_by_count":7}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2017-10-20T00:00:00"}